Misplaced Pages

Latest revision as of 03:01, 25 December 2024

Birth control, also known as contraception, anticonception, and fertility control, is the use of methods or devices to prevent pregnancy. Birth control has been used since ancient times, but effective and safe methods of birth control only became available in the 20th century. Planning, making available, and using human birth control is called family planning. Some cultures limit or discourage access to birth control because they consider it to be morally, religiously, or politically undesirable.

The World Health Organization and United States Centers for Disease Control and Prevention provide guidance on the safety of birth control methods among women with specific medical conditions. The most effective methods of birth control are sterilization by means of vasectomy in males and bilateral salpingectomy in females, intrauterine devices (IUDs), and implantable birth control. This is followed by a number of hormone-based methods including contraceptive pills, patches, vaginal rings, and injections. Less effective methods include physical barriers such as condoms, diaphragms and birth control sponges and fertility awareness methods. The least effective methods are spermicides and withdrawal by the male before ejaculation. Sterilization, while highly effective, is not usually reversible; all other methods are reversible, most immediately upon stopping them. Safe sex practices, such as with the use of condoms or female condoms, can also help prevent sexually transmitted infections. Other methods of birth control do not protect against sexually transmitted infections. Emergency birth control can prevent pregnancy if taken within 72 to 120 hours after unprotected sex. Some argue not having sex is also a form of birth control, but abstinence-only sex education may increase teenage pregnancies if offered without birth control education, due to non-compliance.

In teenagers, pregnancies are at greater risk of poor outcomes. Comprehensive sex education and access to birth control decreases the rate of unintended pregnancies in this age group. While all forms of birth control can generally be used by young people, long-acting reversible birth control such as implants, IUDs, or vaginal rings are more successful in reducing rates of teenage pregnancy. After the delivery of a child, a woman who is not exclusively breastfeeding may become pregnant again after as few as four to six weeks. Some methods of birth control can be started immediately following the birth, while others require a delay of up to six months. In women who are breastfeeding, progestin-only methods are preferred over combined oral birth control pills. In women who have reached menopause, it is recommended that birth control be continued for one year after the last menstrual period.

About 222 million women who want to avoid pregnancy in developing countries are not using a modern birth control method. Birth control use in developing countries has decreased the number of deaths during or around the time of pregnancy by 40% (about 270,000 deaths prevented in 2008) and could prevent 70% if the full demand for birth control were met. By lengthening the time between pregnancies, birth control can improve adult women's delivery outcomes and the survival of their children. In the developing world, women's earnings, assets, and weight, as well as their children's schooling and health, all improve with greater access to birth control. Birth control increases economic growth because of fewer dependent children, more women participating in the workforce, and/or less use of scarce resources.

Methods

Birth control methods include barrier methods, hormonal birth control, intrauterine devices (IUDs), sterilization, and behavioral methods. They are used before or during sex while emergency contraceptives are effective for up to five days after sex. Effectiveness is generally expressed as the percentage of women who become pregnant using a given method during the first year, and sometimes as a lifetime failure rate among methods with high effectiveness, such as tubal ligation.

Birth control methods fall into two main categories: male contraception and female contraception. Common male contraceptives are withdrawal, condoms, and vasectomy. Female contraception is more developed compared to male contraception, these include contraceptive pills (combination and progestin-only pill), hormonal or non-hormonal IUD, patch, vaginal ring, diaphragm, shot, implant, fertility awareness, and tubal ligation.

The most effective methods are those that are long acting and do not require ongoing health care visits. Surgical sterilization, implantable hormones, and intrauterine devices all have first-year failure rates of less than 1%. Hormonal contraceptive pills, patches or vaginal rings, and the lactational amenorrhea method (LAM), if adhered to strictly, can also have first-year (or for LAM, first-6-month) failure rates of less than 1%. With typical use, first-year failure rates are considerably higher, at 9%, due to inconsistent use. Other methods such as condoms, diaphragms, and spermicides have higher first-year failure rates even with perfect usage. The American Academy of Pediatrics recommends long acting reversible birth control as first line for young individuals.

While all methods of birth control have some potential adverse effects, the risk is less than that of pregnancy. After stopping or removing many methods of birth control, including oral contraceptives, IUDs, implants and injections, the rate of pregnancy during the subsequent year is the same as for those who used no birth control.

For individuals with specific health problems, certain forms of birth control may require further investigations. For women who are otherwise healthy, many methods of birth control should not require a medical exam—including birth control pills, injectable or implantable birth control, and condoms. For example, a pelvic exam, breast exam, or blood test before starting birth control pills does not appear to affect outcomes. In 2009, the World Health Organization (WHO) published a detailed list of medical eligibility criteria for each type of birth control.

Hormonal

Hormonal contraception is available in a number of different forms, including oral pills, implants under the skin, injections, patches, IUDs and a vaginal ring. They are currently available only for women, although hormonal contraceptives for men have been and are being clinically tested. There are two types of oral birth control pills, the combined oral contraceptive pills (which contain both estrogen and a progestin) and the progestogen-only pills (sometimes called minipills). If either is taken during pregnancy, they do not increase the risk of miscarriage nor cause birth defects. Both types of birth control pills prevent fertilization mainly by inhibiting ovulation and thickening cervical mucus. They may also change the lining of the uterus and thus decrease implantation. Their effectiveness depends on the user's adherence to taking the pills.

Combined hormonal contraceptives are associated with a slightly increased risk of venous and arterial blood clots. Venous clots, on average, increase from 2.8 to 9.8 per 10,000 women years which is still less than that associated with pregnancy. Due to this risk, they are not recommended in women over 35 years of age who continue to smoke. Due to the increased risk, they are included in decision tools such as the DASH score and PERC rule used to predict the risk of blood clots.

The effect on sexual drive is varied, with increase or decrease in some but with no effect in most. Combined oral contraceptives reduce the risk of ovarian cancer and endometrial cancer and do not change the risk of breast cancer. They often reduce menstrual bleeding and painful menstruation cramps. The lower doses of estrogen released from the vaginal ring may reduce the risk of breast tenderness, nausea, and headache associated with higher dose estrogen products.

Progestin-only pills, injections and intrauterine devices are not associated with an increased risk of blood clots and may be used by women with a history of blood clots in their veins. In those with a history of arterial blood clots, non-hormonal birth control or a progestin-only method other than the injectable version should be used. Progestin-only pills may improve menstrual symptoms and can be used by breastfeeding women as they do not affect milk production. Irregular bleeding may occur with progestin-only methods, with some users reporting no periods. The progestins drospirenone and desogestrel minimize the androgenic side effects but increase the risks of blood clots and are thus not first line. The perfect use first-year failure rate of injectable progestin is 0.2%; the typical use first failure rate is 6%.

• Three varieties of birth control pills in calendar oriented packaging
• Birth control pills
• A transdermal contraceptive patch
• A NuvaRing vaginal ring

Barrier

Barrier contraceptives are devices that attempt to prevent pregnancy by physically preventing sperm from entering the uterus. They include male condoms, female condoms, cervical caps, diaphragms, and contraceptive sponges with spermicide.

Globally, condoms are the most common method of birth control. Male condoms are put on a man's erect penis and physically block ejaculated sperm from entering the body of a sexual partner. Modern condoms are most often made from latex, but some are made from other materials such as polyurethane, or lamb's intestine. Female condoms are also available, most often made of nitrile, latex or polyurethane. Male condoms have the advantage of being inexpensive, easy to use, and have few adverse effects. Making condoms available to teenagers does not appear to affect the age of onset of sexual activity or its frequency. In Japan, about 80% of couples who are using birth control use condoms, while in Germany this number is about 25%, and in the United States it is 18%.

Male condoms and the diaphragm with spermicide have typical use first-year failure rates of 18% and 12%, respectively. With perfect use condoms are more effective with a 2% first-year failure rate versus a 6% first-year rate with the diaphragm. Condoms have the additional benefit of helping to prevent the spread of some sexually transmitted infections such as HIV/AIDS, however, condoms made from animal intestine do not.

Contraceptive sponges combine a barrier with a spermicide. Like diaphragms, they are inserted vaginally before intercourse and must be placed over the cervix to be effective. Typical failure rates during the first year depend on whether or not a woman has previously given birth, being 24% in those who have and 12% in those who have not. The sponge can be inserted up to 24 hours before intercourse and must be left in place for at least six hours afterward. Allergic reactions and more severe adverse effects such as toxic shock syndrome have been reported.

• A rolled up male condom.
• An unrolled male latex condom
• A polyurethane female condom
• A diaphragm vaginal-cervical barrier, in its case with a quarter U.S. coin.
• A contraceptive sponge set inside its open package.

Intrauterine devices

The current intrauterine devices (IUD) are small devices, often T-shaped, containing either copper or levonorgestrel, which are inserted into the uterus. They are one form of long-acting reversible contraception which are the most effective types of reversible birth control. Failure rates with the copper IUD is about 0.8% while the levonorgestrel IUD has a failure rates of 0.2% in the first year of use. Among types of birth control, they, along with birth control implants, result in the greatest satisfaction among users. As of 2007, IUDs are the most widely used form of reversible contraception, with more than 180 million users worldwide.

Evidence supports effectiveness and safety in adolescents and those who have and have not previously had children. IUDs do not affect breastfeeding and can be inserted immediately after delivery. They may also be used immediately after an abortion. Once removed, even after long term use, fertility returns to normal immediately.

While copper IUDs may increase menstrual bleeding and result in more painful cramps, hormonal IUDs may reduce menstrual bleeding or stop menstruation altogether. Cramping can be treated with painkillers like non-steroidal anti-inflammatory drugs. Other potential complications include expulsion (2–5%) and rarely perforation of the uterus (less than 0.7%). A previous model of the intrauterine device (the Dalkon shield) was associated with an increased risk of pelvic inflammatory disease; however, the risk is not affected with current models in those without sexually transmitted infections around the time of insertion. IUDs appear to decrease the risk of ovarian cancer.

Sterilization

Two broad categories exist, surgical and non-surgical.

Surgical sterilization is available in the form of tubal ligation for women and vasectomy for men. Tubal ligation decreases the risk of ovarian cancer. Short term complications are twenty times less likely from a vasectomy than a tubal ligation. After a vasectomy, there may be swelling and pain of the scrotum which usually resolves in one or two weeks. Chronic scrotal pain associated with negative impact on quality of life occurs after vasectomy in about 1–2% of men. With tubal ligation, complications occur in 1 to 2 percent of procedures with serious complications usually due to the anesthesia. Neither method offers protection from sexually transmitted infections. Sometimes, salpingectomy is also used for sterilization in women.

Non-surgical sterilization methods have also been explored. Fahim et al. found that heat exposure, especially high-intensity ultrasound, was effective either for temporary or permanent contraception depending on the dose, e.g. selective destruction of germ cells and Sertoli cells without affecting Leydig cells or testosterone levels. Chemical, e.g. drug-based methods are also available, e.g. orally-administered Lonidamine for temporary, or permanent (depending on the dose) fertility management. Boris provides a method for chemically inducing either temporary or non-reversible sterility, depending on the dose, "Permanent sterility in human males can be obtained by a single oral dosage containing from about 18 mg/kg to about 25 mg/kg".

The permanence of this decision may cause regret in some men and women. Of women who have undergone tubal ligation after the age of 30, about 6% regret their decision, as compared with 20–24% of women who received sterilization within one year of delivery and before turning 30, and 6% in nulliparous women sterilized before the age of 30. By contrast, less than 5% of men are likely to regret sterilization. Men who are more likely to regret sterilization are younger, have young or no children, or have an unstable marriage. In a survey of biological parents, 9% stated they would not have had children if they were able to do it over again.

Although sterilization is considered a permanent procedure, it is possible to attempt a tubal reversal to reconnect the fallopian tubes or a vasectomy reversal to reconnect the vasa deferentia. In women, the desire for a reversal is often associated with a change in spouse. Pregnancy success rates after tubal reversal are between 31 and 88 percent, with complications including an increased risk of ectopic pregnancy. The number of males who request reversal is between 2 and 6 percent. Rates of success in fathering another child after reversal are between 38 and 84 percent; with success being lower the longer the time period between the vasectomy and the reversal. Sperm extraction followed by in vitro fertilization may also be an option in men.

Behavioral

Behavioral methods involve regulating the timing or method of intercourse to prevent introduction of sperm into the female reproductive tract, either altogether or when an egg may be present. If used perfectly the first-year failure rate may be around 3.4%; however, if used poorly first-year failure rates may approach 85%.

Fertility awareness

Fertility awareness methods involve determining the most fertile days of the menstrual cycle and avoiding unprotected intercourse. Techniques for determining fertility include monitoring basal body temperature, cervical secretions, or the day of the cycle. They have typical first-year failure rates of 24%; perfect use first-year failure rates depend on which method is used and range from 0.4% to 5%. The evidence on which these estimates are based, however, is poor as the majority of people in trials stop their use early. Globally, they are used by about 3.6% of couples. If based on both basal body temperature and another primary sign, the method is referred to as symptothermal. First-year failure rates of 20% overall and 0.4% for perfect use have been reported in clinical studies of the symptothermal method. A number of fertility tracking apps are available, as of 2016, but they are more commonly designed to assist those trying to get pregnant rather than prevent pregnancy.

Withdrawal

The withdrawal method (also known as coitus interruptus) is the practice of ending intercourse ("pulling out") before ejaculation. The main risk of the withdrawal method is that the man may not perform the maneuver correctly or in a timely manner. First-year failure rates vary from 4% with perfect usage to 22% with typical usage. It is not considered birth control by some medical professionals.

There is little data regarding the sperm content of pre-ejaculatory fluid. While some tentative research did not find sperm, one trial found sperm present in 10 out of 27 volunteers. The withdrawal method is used as birth control by about 3% of couples.

Abstinence

Sexual abstinence may be used as a form of birth control, meaning either not engaging in any type of sexual activity, or specifically not engaging in vaginal intercourse, while engaging in other forms of non-vaginal sex. Complete sexual abstinence is 100% effective in preventing pregnancy. However, among those who take a pledge to abstain from premarital sex, as many as 88% who engage in sex, do so prior to marriage. The choice to abstain from sex cannot protect against pregnancy as a result of rape, and public health efforts emphasizing abstinence to reduce unwanted pregnancy may have limited effectiveness, especially in developing countries and among disadvantaged groups.

Deliberate non-penetrative sex without vaginal sex or deliberate oral sex without vaginal sex are also sometimes considered birth control. While this generally avoids pregnancy, pregnancy can still occur with intercrural sex and other forms of penis-near-vagina sex (genital rubbing, and the penis exiting from anal intercourse) where sperm can be deposited near the entrance to the vagina and can travel along the vagina's lubricating fluids.

Abstinence-only sex education does not reduce teenage pregnancy. Teen pregnancy rates and STI rates are generally the same or higher in states where students are given abstinence-only education, as compared with comprehensive sex education. Some authorities recommend that those using abstinence as a primary method have backup methods available (such as condoms or emergency contraceptive pills).

Lactation

The lactational amenorrhea method involves the use of a woman's natural postpartum infertility which occurs after delivery and may be extended by breastfeeding. For a postpartum woman to be infertile (protected from pregnancy), their periods have usually not yet returned (not menstruating), they are exclusively breastfeeding the infant, and the baby is younger than six months. If breastfeeding is the infant's only source of nutrition and the baby is less than 6 months old, 93–99% of women are estimated to have protection from becoming pregnant in the first six months (0.75–7.5% failure rate). The failure rate increases to 4–7% at one year and 13% at two years. Feeding formula, pumping instead of nursing, the use of a pacifier, and feeding solids all increase the chances of becoming pregnant while breastfeeding. In those who are exclusively breastfeeding, about 10% begin having periods before three months and 20% before six months. In those who are not breastfeeding, fertility may return as early as four weeks after delivery.

Emergency

Emergency contraceptive methods are medications (sometimes misleadingly referred to as "morning-after pills") or devices used after unprotected sexual intercourse with the hope of preventing pregnancy. Emergency contraceptives are often given to victims of rape. They work primarily by preventing ovulation or fertilization. They are unlikely to affect implantation, but this has not been completely excluded. A number of options exist, including high dose birth control pills, levonorgestrel, mifepristone, ulipristal and IUDs. All methods have minimal side effects. Providing emergency contraceptive pills to women in advance of sexual activity does not affect rates of sexually transmitted infections, condom use, pregnancy rates, or sexual risk-taking behavior. In a UK study, when a three-month "bridge" supply of the progestogen-only pill was provided by a pharmacist along with emergency contraception after sexual activity, this intervention was shown to increase the likelihood that the person would begin to use an effective method of long-term contraception.

Levonorgestrel pills, when used within 3 days, decrease the chance of pregnancy after a single episode of unprotected sex or condom failure by 70% (resulting in a pregnancy rate of 2.2%). Ulipristal, when used within 5 days, decreases the chance of pregnancy by about 85% (pregnancy rate 1.4%) and is more effective than levonorgestrel. Mifepristone is also more effective than levonorgestrel, while copper IUDs are the most effective method. IUDs can be inserted up to five days after intercourse and prevent about 99% of pregnancies after an episode of unprotected sex (pregnancy rate of 0.1 to 0.2%). This makes them the most effective form of emergency contraceptive. In those who are overweight or obese, levonorgestrel is less effective and an IUD or ulipristal is recommended.

Dual protection

Dual protection is the use of methods that prevent both sexually transmitted infections and pregnancy. This can be with condoms either alone or along with another birth control method or by the avoidance of penetrative sex.

If pregnancy is a high concern, using two methods at the same time is reasonable. For example, two forms of birth control are recommended in those taking the anti-acne drug isotretinoin or anti-epileptic drugs like carbamazepine, due to the high risk of birth defects if taken during pregnancy.

Effects

Health

Contraceptive use in developing countries is estimated to have decreased the number of maternal deaths by 40% (about 270,000 deaths prevented in 2008) and could prevent 70% of deaths if the full demand for birth control were met. These benefits are achieved by reducing the number of unplanned pregnancies that subsequently result in unsafe abortions and by preventing pregnancies in those at high risk.

Birth control also improves child survival in the developing world by lengthening the time between pregnancies. In this population, outcomes are worse when a mother gets pregnant within eighteen months of a previous delivery. Delaying another pregnancy after a miscarriage, however, does not appear to alter risk and women are advised to attempt pregnancy in this situation whenever they are ready.

Teenage pregnancies, especially among younger teens, are at greater risk of adverse outcomes including early birth, low birth weight, and death of the infant. In 2012 in the United States 82% of pregnancies in those between the ages of 15 and 19 years old are unplanned. Comprehensive sex education and access to birth control are effective in decreasing pregnancy rates in this age group.

Birth control methods, especially hormonal methods, can also have undesirable side effects. Intensity of side effects can range from minor to debilitating, and varies with individual experiences. These most commonly include change in menstruation regularity and flow, nausea, breast tenderness, headaches, weight gain, and mood changes (specifically an increase in depression and anxiety). Additionally, hormonal contraception can contribute to bone mineral density loss, impaired glucose metabolism, increased risk of venous thromboembolism. Comprehensive sex education and transparent discussion of birth control side effects and contraindications between healthcare provider and patient is imperative.

Finances

In the developing world, birth control increases economic growth due to there being fewer dependent children and thus more women participating in or increased contribution to the workforce – as they are usually the primary caregiver for children. Women's earnings, assets, body mass index, and their children's schooling and body mass index all improve with greater access to birth control. Family planning, via the use of modern birth control, is one of the most cost-effective health interventions. For every dollar spent, the United Nations estimates that two to six dollars are saved. These cost savings are related to preventing unplanned pregnancies and decreasing the spread of sexually transmitted illnesses. While all methods are beneficial financially, the use of copper IUDs resulted in the greatest savings.

The total medical cost for a pregnancy, delivery and care of a newborn in the United States is on average $21,000 for a vaginal delivery and $31,000 for a caesarean delivery as of 2012. In most other countries, the cost is less than half. For a child born in 2011, an average US family will spend $235,000 over 17 years to raise them.

Prevalence

Globally, as of 2009, approximately 60% of those who are married and able to have children use birth control. How frequently different methods are used varies widely between countries. The most common method in the developed world is condoms and oral contraceptives, while in Africa it is oral contraceptives and in Latin America and Asia it is sterilization. In the developing world overall, 35% of birth control is via female sterilization, 30% is via IUDs, 12% is via oral contraceptives, 11% is via condoms, and 4% is via male sterilization.

While less used in the developed countries than the developing world, the number of women using IUDs as of 2007 was more than 180 million. Avoiding sex when fertile is used by about 3.6% of women of childbearing age, with usage as high as 20% in areas of South America. As of 2005, 12% of couples are using a male form of birth control (either condoms or a vasectomy) with higher rates in the developed world. Usage of male forms of birth control has decreased between 1985 and 2009. Contraceptive use among women in Sub-Saharan Africa has risen from about 5% in 1991 to about 30% in 2006.

As of 2012, 57% of women of childbearing age want to avoid pregnancy (867 of 1,520 million). About 222 million women, however, were not able to access birth control, 53 million of whom were in sub-Saharan Africa and 97 million of whom were in Asia. This results in 54 million unplanned pregnancies and nearly 80,000 maternal deaths a year. Part of the reason that many women are without birth control is that many countries limit access due to religious or political reasons, while another contributor is poverty. Due to restrictive abortion laws in Sub-Saharan Africa, many women turn to unlicensed abortion providers for unintended pregnancy, resulting in about 2–4% obtaining unsafe abortions each year.

History

Early history

The Egyptian Ebers Papyrus from 1550 BC and the Kahun Papyrus from 1850 BC have within them some of the earliest documented descriptions of birth control: the use of honey, acacia leaves and lint to be placed in the vagina to block sperm. Silphium, a species of giant fennel native to north Africa, may have been used as birth control in ancient Greece and the ancient Near East. Due to its desirability, by the first century AD, it had become so rare that it was worth more than its weight in silver and, by late antiquity, it was fully extinct. Most methods of birth control used in antiquity were probably ineffective.

The ancient Greek philosopher Aristotle (c. 384–322 BC) recommended applying cedar oil to the womb before intercourse, a method which was probably only effective on occasion. A Hippocratic text On the Nature of Women recommended that a woman drink a copper salt dissolved in water, which it claimed would prevent pregnancy for a year. This method was not only ineffective, but also dangerous, as the later medical writer Soranus of Ephesus (c. 98–138 AD) pointed out. Soranus attempted to list reliable methods of birth control based on rational principles. He rejected the use of superstition and amulets and instead prescribed mechanical methods such as vaginal plugs and pessaries using wool as a base covered in oils or other gummy substances. Many of Soranus's methods were probably also ineffective.

In medieval Europe, any effort to halt pregnancy was deemed immoral by the Catholic Church, although it is believed that women of the time still used a number of birth control measures, such as coitus interruptus and inserting lily root and rue into the vagina. Women in the Middle Ages were also encouraged to tie weasel testicles around their thighs during sex to prevent pregnancy. The oldest condoms discovered to date were recovered in the ruins of Dudley Castle in England, and are dated back to 1640. They were made of animal gut, and were most likely used to prevent the spread of sexually transmitted infections during the English Civil War. Casanova, living in 18th-century Italy, described the use of a lambskin covering to prevent pregnancy; however, condoms only became widely available in the 20th century.

Birth control movement

The birth control movement developed during the 19th and early 20th centuries. The Malthusian League, based on the ideas of Thomas Malthus, was established in 1877 in the United Kingdom to educate the public about the importance of family planning and to advocate for getting rid of penalties for promoting birth control. It was founded during the "Knowlton trial" of Annie Besant and Charles Bradlaugh, who were prosecuted for publishing on various methods of birth control.

In the United States, Margaret Sanger and Otto Bobsein popularized the phrase "birth control" in 1914. Sanger primarily advocated for birth control on the idea that it would prevent women from seeking unsafe abortions, but during her lifetime, she began to campaign for it on the grounds that it would reduce mental and physical defects. She was mainly active in the United States but had gained an international reputation by the 1930s. At the time, under the Comstock Law, distribution of birth control information was illegal. She jumped bail in 1914 after her arrest for distributing birth control information and left the United States for the United Kingdom. In the U.K., Sanger, influenced by Havelock Ellis, further developed her arguments for birth control. She believed women needed to enjoy sex without fearing a pregnancy. During her time abroad, Sanger also saw a more flexible diaphragm in a Dutch clinic, which she thought was a better form of contraceptive. Once Sanger returned to the United States, she established a short-lived birth-control clinic with the help of her sister, Ethel Bryne, based in the Brownville section of Brooklyn, New York in 1916. It was shut down after eleven days and resulted in her arrest. The publicity surrounding the arrest, trial, and appeal sparked birth control activism across the United States. Besides her sister, Sanger was helped in the movement by her first husband, William Sanger, who distributed copies of "Family Limitation." Sanger's second husband, James Noah H. Slee, would also later become involved in the movement, acting as its main funder. Sanger also contributed to the funding of research into hormonal contraceptives in the 1950s. She helped fund research John Rock, and biologist Gregory Pincus that resulted in the first hormonal contraceptive pill, later called Enovid. The first human trials of the pill were done on patients in the Worcester State Psychiatric Hospital, after which clinical testing was done in Puerto Rico before Enovid was approved for use in the U.S.. The people participating in these trials were not fully informed on the medical implications of the pill, and often had minimal to no other family planning options. The newly approved birth control method was not made available to the participants after the trials, and contraceptives are still not widely accessible in Puerto Rico.

The increased use of birth control was seen by some as a form of social decay. A decrease of fertility was seen as a negative. Throughout the Progressive Era (1890–1920), there was an increase of voluntary associations aiding the contraceptive movement. These organizations failed to enlist more than 100,000 women because the use of birth control was often compared to eugenics; however, there were women seeking a community with like-minded women. The ideology that surrounded birth control started to gain traction during the Progressive Era due to voluntary associations establishing community. Birth control was unlike the Victorian Era because women wanted to manage their sexuality. The use of birth control was another form of self-interest women clung to. This was seen as women began to gravitate towards strong figures, like the Gibson Girl.

The first permanent birth-control clinic was established in Britain in 1921 by Marie Stopes working with the Malthusian League. The clinic, run by midwives and supported by visiting doctors, offered women's birth-control advice and taught them the use of a cervical cap. Her clinic made contraception acceptable during the 1920s by presenting it in scientific terms. In 1921, Sanger founded the American Birth Control League, which later became the Planned Parenthood Federation of America. In 1924 the Society for the Provision of Birth Control Clinics was founded to campaign for municipal clinics; this led to the opening of a second clinic in Greengate, Salford in 1926. Throughout the 1920s, Stopes and other feminist pioneers, including Dora Russell and Stella Browne, played a major role in breaking down taboos about sex. In April 1930 the Birth Control Conference assembled 700 delegates and was successful in bringing birth control and abortion into the political sphere – three months later, the Ministry of Health, in the United Kingdom, allowed local authorities to give birth-control advice in welfare centres.

The National Birth Control Association was founded in Britain in 1931, and became the Family Planning Association eight years later. The Association amalgamated several British birth control-focused groups into 'a central organisation' for administering and overseeing birth control in Britain. The group incorporated the Birth Control Investigation Committee, a collective of physicians and scientists that was founded to investigate scientific and medical aspects of contraception with 'neutrality and impartiality'. Subsequently, the Association effected a series of 'pure' and 'applied' product and safety standards that manufacturers must meet to ensure their contraceptives could be prescribed as part of the Association's standard two-part-technique combining 'a rubber appliance to protect the mouth of the womb' with a 'chemical preparation capable of destroying... sperm'. Between 1931 and 1959, the Association founded and funded a series of tests to assess chemical efficacy and safety and rubber quality. These tests became the basis for the Association's Approved List of contraceptives, which was launched in 1937, and went on to become an annual publication that the expanding network of FPA clinics relied upon as a means to 'establish facts and to publish these facts as a basis on which a sound public and scientific opinion can be built'.

In 1936, the United States Court of Appeals for the Second Circuit ruled in United States v. One Package of Japanese Pessaries that medically prescribing contraception to save a person's life or well-being was not illegal under the Comstock Laws. Following this decision, the American Medical Association Committee on Contraception revoked its 1936 statement condemning birth control. A national survey in 1937 showed 71 percent of the adult population supported the use of contraception. By 1938, 374 birth control clinics were running in the United States despite their advertisement still being illegal. First Lady Eleanor Roosevelt publicly supported birth control and family planning. The restrictions on birth control in the Comstock laws were effectively rendered null and void by Supreme Court decisions Griswold v. Connecticut (1965) and Eisenstadt v. Baird (1972). In 1966, President Lyndon B. Johnson started endorsing public funding for family planning services, and the Federal Government began subsidizing birth control services for low-income families. The Affordable Care Act, passed into law on March 23, 2010, under President Barack Obama, requires all plans in the Health Insurance Marketplace to cover contraceptive methods. These include barrier methods, hormonal methods, implanted devices, emergency contraceptives, and sterilization procedures.

Modern methods

In 1909, Richard Richter developed the first intrauterine device made from silkworm gut, which was further developed and marketed in Germany by Ernst Gräfenberg in the late 1920s. In 1951, an Austrian-born American chemist, named Carl Djerassi at Syntex in Mexico City made the hormones in progesterone pills using Mexican yams (Dioscorea mexicana). Djerassi had chemically created the pill but was not equipped to distribute it to patients. Meanwhile, Gregory Pincus and John Rock with help from the Planned Parenthood Federation of America developed the first birth control pills in the 1950s, such as mestranol/noretynodrel, which became publicly available in the 1960s through the Food and Drug Administration under the name Enovid. Medical abortion became an alternative to surgical abortion with the availability of prostaglandin analogs in the 1970s and mifepristone in the 1980s.

Society and culture

Legal positions

Human rights agreements require most governments to provide family planning and contraceptive information and services. These include the requirement to create a national plan for family planning services, remove laws that limit access to family planning, ensure that a wide variety of safe and effective birth control methods are available including emergency contraceptives, make sure there are appropriately trained healthcare providers and facilities at an affordable price, and create a process to review the programs implemented. If governments fail to do the above it may put them in breach of binding international treaty obligations.

In the United States, the 1965 Supreme Court decision Griswold v. Connecticut overturned a state law prohibiting dissemination of contraception information based on a constitutional right to privacy for marital relationships. In 1972, Eisenstadt v. Baird extended this right to privacy to single people.

In 2010, the United Nations launched the Every Woman Every Child movement to assess the progress toward meeting women's contraceptive needs. The initiative has set a goal of increasing the number of users of modern birth control by 120 million women in the world's 69 poorest countries by 2020. Additionally, they aim to eradicate discrimination against girls and young women who seek contraceptives. The American Congress of Obstetricians and Gynecologists (ACOG) recommended in 2014 that oral birth control pills should be over the counter medications.

Since at least the 1870s, American religious, medical, legislative, and legal commentators have debated contraception laws. Ana Garner and Angela Michel have found that in these discussions men often attach reproductive rights to moral and political matters, as part of an ongoing attempt to regulate human bodies. In press coverage between 1873 and 2013 they found a divide between institutional ideology and real-life experiences of women.

Religious views

Religions vary widely in their views of the ethics of birth control. The Roman Catholic Church re-affirmed its teachings in 1968 that only natural family planning is permissible, although large numbers of Catholics in developed countries accept and use modern methods of birth control. The Greek Orthodox Church admits a possible exception to its traditional teaching forbidding the use of artificial contraception, if used within marriage for certain purposes, including the spacing of births. Among Protestants, there is a wide range of views from supporting none, such as in the Quiverfull movement, to allowing all methods of birth control. Views in Judaism range from the stricter Orthodox sect, which prohibits all methods of birth control, to the more relaxed Reform sect, which allows most. Hindus may use both natural and modern contraceptives. A common Buddhist view is that preventing conception is acceptable, while intervening after conception has occurred is not. In Islam, contraceptives are allowed if they do not threaten health, although their use is discouraged by some.

World Contraception Day

September 26 is World Contraception Day, devoted to raising awareness and improving education about sexual and reproductive health, with a vision of a world where every pregnancy is wanted. It is supported by a group of governments and international NGOs, including the Office of Population Affairs, the Asian Pacific Council on Contraception, Centro Latinamericano Salud y Mujer, the European Society of Contraception and Reproductive Health, the German Foundation for World Population, the International Federation of Pediatric and Adolescent Gynecology, International Planned Parenthood Federation, the Marie Stopes International, Population Services International, the Population Council, the United States Agency for International Development (USAID), and Women Deliver.

Misconceptions

There are a number of common misconceptions regarding sex and pregnancy. Douching after sexual intercourse is not an effective form of birth control. Additionally, it is associated with a number of health problems and thus is not recommended. Women can become pregnant the first time they have sexual intercourse and in any sexual position. It is possible, although not very likely, to become pregnant during menstruation. Contraceptive use, regardless of its duration and type, does not have a negative effect on the ability of women to conceive following termination of use and does not significantly delay fertility. Women who use oral contraceptives for a longer duration may have a slightly lower rate of pregnancy than do women using oral contraceptives for a shorter period of time, possibly due to fertility decreasing with age.

Accessibility

Access to birth control may be affected by finances and the laws within a region or country. In the United States African American, Hispanic, and young women are disproportionately affected by limited access to birth control, as a result of financial disparity. For example, Hispanic and African American women often lack insurance coverage and are more often poor. New immigrants in the United States are not offered preventive care such as birth control.

In the United Kingdom contraception can be obtained free of charge via contraception clinics, sexual health or GUM (genitourinary medicine) clinics, via some GP surgeries, some young people's services and pharmacies.

In September 2021, France announced that women aged under 25 in France will be offered free contraception from 2022. It was elaborated that they "would not be charged for medical appointments, tests, or other medical procedures related to birth control" and that this would "cover hormonal contraception, biological tests that go with it, the prescription of contraception and all care related to this contraception".

From August 2022 onwards contraception for women aged between 17 and 25 years will be free in the Republic of Ireland.

Public provisioning for contraception

In most parts of the world, the political attitude to contraception determines whether and how much state provisioning of contraceptive care occurs. In the United States, for example, the Republican party and the Democratic party have held opposite positions, contributing to continuous policy shifts over the years. In the 2010s, policies, and attitudes to contraceptive care shifted abruptly between Obama's and Trump's administrations. The Trump administration extensively overturned the efforts for contraceptive care, and reduced federal spending, compared to efforts and funding during the Obama administration.

Advocacy

Free the Pill, a collaboration between Advocates for Youth and Ibis Reproductive Health are working to bring birth control over-the-counter, covered by insurance with no age-restriction throughout the United States.

Approval

On July 13, 2023, the first US daily oral nonprescription over-the-counter birth control pill was approved for manufacturer by the FDA. The pill, Opill is expected to be more effective in preventing unintended pregnancies than condoms are. Opill is expected to be available in 2024 but the price has yet to be set. Perrigo, a pharmaceutical company based in Dublin is the manufacturer.

Research directions

Females

Improvements of existing birth control methods are needed, as around half of those who get pregnant unintentionally are using birth control at the time. A number of alterations of existing contraceptive methods are being studied, including a better female condom, an improved diaphragm, a patch containing only progestin, and a vaginal ring containing long-acting progesterone. This vaginal ring appears to be effective for three or four months and is currently available in some areas of the world. For women who rarely have sex, the taking of the hormonal birth control levonorgestrel around the time of sex looks promising.

A number of methods to perform sterilization via the cervix are being studied. One involves putting quinacrine in the uterus which causes scarring and infertility. While the procedure is inexpensive and does not require surgical skills, there are concerns regarding long-term side effects. Another substance, polidocanol, which functions in the same manner is being looked at. A device called Essure, which expands when placed in the fallopian tubes and blocks them, was approved in the United States in 2002. In 2016, a black boxed warning regarding potentially serious side effects was added, and in 2018, the device was discontinued.

Males

Despite high levels of interest in male contraception, progress been stymied by a lack of industry involvement. Most funding for male contraceptive research is derived from government or philanthropic sources.

A number of novel contraceptive methods based on hormonal and non-hormonal mechanisms of action are in various stages of research and development, up to and including clinical trials, including gels, pills, injectables, implants, wearables, and oral contraceptives.

Recent avenues of research include proteins and genes required for male fertility. For instance, the serine/threonine-protein kinase 33 (STK33) is a testis-enriched kinase that is indispensable for male fertility in humans and mice. An inhibitor of this kinase, CDD-2807, has recently been identified and induced reversible male infertility without measurable toxicity in mice. Such an inhibitor would be a potent male contraceptive if it passed safety and efficacy tests.

Animals

Neutering or spaying, which involves removing some of the reproductive organs, is often carried out as a method of birth control in household pets. Many animal shelters require these procedures as part of adoption agreements. In large animals the surgery is known as castration.

Birth control is also being considered as an alternative to hunting as a means of controlling overpopulation in wild animals. Contraceptive vaccines have been found to be effective in a number of different animal populations. Kenyan goat herders fix a skirt, called an olor, to male goats to prevent them from impregnating female goats.

See also

• Human population planning
• Immunocontraception

References

1. "Definition of Birth control". MedicineNet. Archived from the original on August 6, 2012. Retrieved August 9, 2012.
2. Schreiber CA, Barnhart K (2014). "Chapter 36 - Contraception". Yen & Jaffe's Reproductive Endocrinology (Seventh Edition). Saunders. pp. 890–908.e3. ISBN 978-1-4557-2758-2.
3. ^ Hanson SJ, Burke AE (2010). "Fertility control: contraception, sterilization, and abortion". In Hurt KJ, Guile MW, Bienstock JL, Fox HE, Wallach EE (eds.). The Johns Hopkins manual of gynecology and obstetrics (4th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. pp. 382–395. ISBN 978-1-60547-433-5.
4. Oxford English Dictionary. Oxford University Press. 2012.
5. World Health Organization (WHO). "Family planning". Health topics. World Health Organization (WHO). Archived from the original on March 18, 2016. Retrieved March 28, 2016.
6. Medical eligibility criteria for contraceptive use (Fifth ed.). Geneva, Switzerland: World Health Organization. 2015. ISBN 978-92-4-154915-8. OCLC 932048744.
7. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. (July 2016). "U.S. Medical Eligibility Criteria for Contraceptive Use, 2016". MMWR. Recommendations and Reports. 65 (3): 1–103. doi:10.15585/mmwr.rr6503a1. PMID 27467196.
8. ^ World Health Organization Department of Reproductive Health and Research (2011). Family planning: A global handbook for providers: Evidence-based guidance developed through worldwide collaboration (PDF) (Rev. and Updated ed.). Geneva: WHO and Center for Communication Programs. ISBN 978-0-9788563-7-3. Archived (PDF) from the original on September 21, 2013.
9. Taliaferro LA, Sieving R, Brady SS, Bearinger LH (December 2011). "We have the evidence to enhance adolescent sexual and reproductive health—do we have the will?". Adolescent Medicine. 22 (3): 521–43, xii. PMID 22423463.
10. ^ Chin HB, Sipe TA, Elder R, Mercer SL, Chattopadhyay SK, Jacob V, et al. (March 2012). "The effectiveness of group-based comprehensive risk-reduction and abstinence education interventions to prevent or reduce the risk of adolescent pregnancy, human immunodeficiency virus, and sexually transmitted infections: two systematic reviews for the Guide to Community Preventive Services". American Journal of Preventive Medicine. 42 (3): 272–94. doi:10.1016/j.amepre.2011.11.006. PMID 22341164.
11. ^ Gizzo S, Fanelli T, Di Gangi S, Saccardi C, Patrelli TS, Zambon A, et al. (October 2012). "Nowadays which emergency contraception? Comparison between past and present: latest news in terms of clinical efficacy, side effects and contraindications". Gynecological Endocrinology. 28 (10): 758–63. doi:10.3109/09513590.2012.662546. PMID 22390259. S2CID 39676240.
12. Selected practice recommendations for contraceptive use (2nd ed.). Geneva: World Health Organization. 2004. p. 13. ISBN 978-92-4-156284-3. Archived from the original on September 8, 2017.
13. DiCenso A, Guyatt G, Willan A, Griffith L (June 2002). "Interventions to reduce unintended pregnancies among adolescents: systematic review of randomised controlled trials". BMJ. 324 (7351): 1426. doi:10.1136/bmj.324.7351.1426. PMC 115855. PMID 12065267.
14. Duffy K, Lynch DA, Santinelli J, Santelli J (December 2008). "Government support for abstinence-only-until-marriage education". Clinical Pharmacology and Therapeutics. 84 (6): 746–8. doi:10.1038/clpt.2008.188. PMID 18923389. S2CID 19499439. Archived from the original on December 11, 2008.
15. ^ Black AY, Fleming NA, Rome ES (April 2012). "Pregnancy in adolescents". Adolescent Medicine. 23 (1): 123–38, xi. PMID 22764559.
16. ^ Rowan SP, Someshwar J, Murray P (April 2012). "Contraception for primary care providers". Adolescent Medicine. 23 (1): 95–110, x–xi. PMID 22764557.
17. ^ World Health Organization Department of Reproductive Health and Research (2011). Family planning: A global handbook for providers: Evidence-based guidance developed through worldwide collaboration (PDF) (Rev. and Updated ed.). Geneva: WHO and Center for Communication Programs. pp. 260–300. ISBN 978-0-9788563-7-3. Archived (PDF) from the original on September 21, 2013.
18. Singh S, Darroch JE (June 2012). "Costs and Benefits of Contraceptive Services: Estimates for 2012" (PDF). United Nations Population Fund: 1. Archived (PDF) from the original on August 5, 2012.
19. ^ Carr B, Gates MF, Mitchell A, Shah R (July 2012). "Giving women the power to plan their families". Lancet. 380 (9837): 80–82. doi:10.1016/S0140-6736(12)60905-2. PMID 22784540. S2CID 205966410. Archived from the original on May 10, 2013.
20. ^ Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A (July 2012). "Contraception and health". Lancet. 380 (9837): 149–156. doi:10.1016/S0140-6736(12)60609-6. PMID 22784533. S2CID 9982712.
21. ^ Ahmed S, Li Q, Liu L, Tsui AO (July 2012). "Maternal deaths averted by contraceptive use: an analysis of 172 countries". Lancet. 380 (9837): 111–125. doi:10.1016/S0140-6736(12)60478-4. PMID 22784531. S2CID 25724866. Archived from the original on May 10, 2013.
22. ^ Canning D, Schultz TP (July 2012). "The economic consequences of reproductive health and family planning". Lancet. 380 (9837): 165–171. doi:10.1016/S0140-6736(12)60827-7. PMID 22784535. S2CID 39280999. Archived from the original on June 2, 2013.
23. Van Braeckel D, Temmerman M, Roelens K, Degomme O (July 2012). "Slowing population growth for wellbeing and development". Lancet. 380 (9837): 84–85. doi:10.1016/S0140-6736(12)60902-7. PMID 22784542. S2CID 10015998. Archived from the original on May 10, 2013.
24. ^ Trussell J (May 2011). "Contraceptive failure in the United States". Contraception. 83 (5): 397–404. doi:10.1016/j.contraception.2011.01.021. PMC 3638209. PMID 21477680.
    Trussell J (2011). "Contraceptive efficacy". In Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 779–863. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734.
25. "U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition". MMWR. Recommendations and Reports. 62 (RR-05). Division Of Reproductive Health, National Center for Chronic Disease Prevention Health Promotion, U.S. Centers for Disease Control and Prevention: 1–60. June 2013. PMID 23784109. Archived from the original on July 10, 2013.
26. Van der Wijden C, Manion C (October 2015). "Lactational amenorrhoea method for family planning". The Cochrane Database of Systematic Reviews. 2015 (10): CD001329. doi:10.1002/14651858.CD001329.pub2. PMC 6823189. PMID 26457821.
27. ^ Blenning CE, Paladine H (December 2005). "An approach to the postpartum office visit". American Family Physician. 72 (12): 2491–2496. PMID 16370405.
28. Edlin G, Golanty E, Brown KM (2000). Essentials for health and wellness (2nd ed.). Sudbury, MA: Jones and Bartlett. p. 161. ISBN 978-0-7637-0909-9. Archived from the original on June 10, 2016.
29. Edmonds DK, ed. (2012). Dewhurst's textbook of obstetrics & gynaecology (8th ed.). Chichester, West Sussex: Wiley-Blackwell. p. 508. ISBN 978-0-470-65457-6. Archived from the original on May 3, 2016.
30. ^ Cunningham FG, Stuart GS (2012). "Contraception and sterilization". In B, Schorge JO, Schaffer JI, Halvorson LM, Bradshaw KD, Cunningham FG (eds.). Williams gynecology (2nd ed.). New York: McGraw-Hill Medical. pp. 132–69. ISBN 978-0-07-171672-7.
31. Committee on Adolescence (October 2014). "Contraception for adolescents". Pediatrics. 134 (4): e1244-56. doi:10.1542/peds.2014-2299. PMC 1070796. PMID 25266430.
32. Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT (November 2011). "Fertility after discontinuation of contraception: a comprehensive review of the literature". Contraception. 84 (5): 465–77. doi:10.1016/j.contraception.2011.04.002. PMID 22018120.
33. ^ Medical eligibility criteria for contraceptive use (PDF) (4th ed.). Geneva: Reproductive Health and Research, World Health Organization. 2009. pp. 1–10. ISBN 978-92-4-156388-8. Archived from the original (PDF) on July 9, 2012.
34. Department of Reproductive Health and Research, Family and Community (2004). Selected practice recommendations for contraceptive use (PDF) (2nd ed.). Geneva: World Health Organization. p. Chapter 31. ISBN 978-92-4-156284-3. Archived from the original (PDF) on July 18, 2013.
35. Tepper NK, Curtis KM, Steenland MW, Marchbanks PA (May 2013). "Physical examination prior to initiating hormonal contraception: a systematic review". Contraception. 87 (5): 650–4. doi:10.1016/j.contraception.2012.08.010. PMID 23121820.
36. ^ World Health Organization Department of Reproductive Health and Research (2011). Family planning: A global handbook for providers: Evidence-based guidance developed through worldwide collaboration (PDF) (Rev. and Updated ed.). Geneva: WHO and Center for Communication Programs. pp. 1–10. ISBN 978-0-9788563-7-3. Archived (PDF) from the original on September 21, 2013.
37. "American Academy of Family Physicians | Choosing Wisely". www.choosingwisely.org. February 24, 2015. Retrieved August 14, 2018.
38. Mackenzie J (December 6, 2013). "The male pill? Bring it on". The Guardian. Archived from the original on May 21, 2014. Retrieved May 20, 2014.
39. Ammer C (2009). "oral contraceptive". The encyclopedia of women's health (6th ed.). New York: Facts On File. pp. 312–15. ISBN 978-0-8160-7407-5.
40. Nelson A, Cwiak C (2011). "Combined oral contraceptives (COCs)". In Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 249–341 . ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734.
41. ^ Hoffman BL (2011). "5 Second-Tier Contraceptive Methods—Very Effective". Williams gynecology (2nd ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-171672-7.
42. ^ Brito MB, Nobre F, Vieira CS (April 2011). "Hormonal contraception and cardiovascular system". Arquivos Brasileiros de Cardiologia. 96 (4): e81-9. doi:10.1590/S0066-782X2011005000022. PMID 21359483.
43. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM (September 2013). "Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis". BMJ. 347: f5298. doi:10.1136/bmj.f5298. PMC 3771677. PMID 24030561.
44. Kurver MJ, van der Wijden CL, Burgers J (October 4, 2012). "[Summary of the Dutch College of General Practitioners' practice guideline 'Contraception']". Nederlands Tijdschrift voor Geneeskunde (in Dutch). 156 (41): A5083. PMID 23062257.
45. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. (June 2012). "Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)". Journal of Thrombosis and Haemostasis. 10 (6): 1019–25. doi:10.1111/j.1538-7836.2012.04735.x. PMID 22489957. S2CID 27149654.
46. Burrows LJ, Basha M, Goldstein AT (September 2012). "The effects of hormonal contraceptives on female sexuality: a review". The Journal of Sexual Medicine. 9 (9): 2213–23. doi:10.1111/j.1743-6109.2012.02848.x. PMID 22788250.
47. ^ Shulman LP (October 2011). "The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives". American Journal of Obstetrics and Gynecology. 205 (4 Suppl): S9-13. doi:10.1016/j.ajog.2011.06.057. PMID 21961825.
48. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. (July 2013). "Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis". Obstetrics and Gynecology. 122 (1): 139–47. doi:10.1097/AOG.0b013e318291c235. PMID 23743450. S2CID 31552437.
49. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI (August 2012). "Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis". BMJ. 345 (aug07 2): e4944. doi:10.1136/bmj.e4944. PMC 3413580. PMID 22872710.
50. Burke AE (October 2011). "The state of hormonal contraception today: benefits and risks of hormonal contraceptives: progestin-only contraceptives". American Journal of Obstetrics and Gynecology. 205 (4 Suppl): S14-7. doi:10.1016/j.ajog.2011.04.033. PMID 21961819.
51. Rott H (August 2012). "Thrombotic risks of oral contraceptives". Current Opinion in Obstetrics & Gynecology. 24 (4): 235–40. doi:10.1097/GCO.0b013e328355871d. PMID 22729096. S2CID 23938634.
52. ^ Neinstein L (2008). Adolescent health care : a practical guide (5th ed.). Philadelphia: Lippincott Williams & Wilkins. p. 624. ISBN 978-0-7817-9256-1. Archived from the original on June 17, 2016.
53. Chaudhuri SK (2007). "Barrier Contraceptives". Practice Of Fertility Control: A Comprehensive Manual (7th ed.). Elsevier India. p. 88. ISBN 978-81-312-1150-2. Archived from the original on April 30, 2016.
54. ^ Hamilton R (2012). Pharmacology for nursing care (8th ed.). St. Louis, MO: Elsevier/Saunders. p. 799. ISBN 978-1-4377-3582-6. Archived from the original on June 3, 2016.
55. Facts for life (4th ed.). New York: United Nations Children's Fund. 2010. p. 141. ISBN 978-92-806-4466-1. Archived from the original on May 13, 2016.
56. Pray WS (2005). Nonprescription product therapeutics (2nd ed.). Philadelphia: Lippincott Williams & Wilkins. p. 414. ISBN 978-0-7817-3498-1. Archived from the original on April 30, 2016.
57. Committee on Adolescence (November 2013). "Condom Use by Adolescents". Pediatrics. 132 (5): 973–981. doi:10.1542/peds.2013-2821. PMID 28448257.
58. Eberhard N (2010). Andrology Male Reproductive Health and Dysfunction (3rd ed.). : Springer-Verlag Berlin Heidelberg. p. 563. ISBN 978-3-540-78355-8. Archived from the original on May 10, 2016.
59. Barbieri JF (2009). Yen and Jaffe's reproductive endocrinology : physiology, pathophysiology, and clinical management (6th ed.). Philadelphia: Saunders/Elsevier. p. 873. ISBN 978-1-4160-4907-4. Archived from the original on May 18, 2016.
60. "Preventing Sexually Transmitted Infections (STIs)". British Columbia Health Link. February 2017. Archived from the original on July 27, 2020. Retrieved March 31, 2018.
61. Kuyoh MA, Toroitich-Ruto C, Grimes DA, Schulz KF, Gallo MF (January 2003). "Sponge versus diaphragm for contraception: a Cochrane review". Contraception. 67 (1): 15–8. doi:10.1016/s0010-7824(02)00434-1. PMID 12521652.
62. Medical eligibility criteria for contraceptive use (4th ed.). Geneva: Reproductive Health and Research, World Health Organization. 2009. p. 88. ISBN 978-92-4-156388-8. Archived from the original on May 15, 2016.
63. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM (May 2012). "Effectiveness of long-acting reversible contraception". The New England Journal of Medicine. 366 (21): 1998–2007. doi:10.1056/NEJMoa1110855. PMID 22621627. S2CID 16812353.
64. Hanson SJ, Burke AE (March 28, 2012). "Fertility Control: Contraception, Sterilization, and Abortion". In Hurt KJ, Guile MW, Bienstock JL, Fox HE, Wallach EE (eds.). The Johns Hopkins manual of gynecology and obstetrics (4th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 232. ISBN 978-1-60547-433-5. Archived from the original on May 12, 2016.
65. ^ Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists (October 2012). "Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices". Obstetrics and Gynecology. 120 (4): 983–8. doi:10.1097/AOG.0b013e3182723b7d. PMID 22996129. S2CID 35516759.
66. ^ Speroff L, Darney PD (2010). A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 242–43. ISBN 978-1-60831-610-6. Archived from the original on May 6, 2016.
67. Black K, Lotke P, Buhling KJ, Zite NB (October 2012). "A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women". The European Journal of Contraception & Reproductive Health Care. 17 (5): 340–50. doi:10.3109/13625187.2012.700744. PMC 4950459. PMID 22834648.
68. ^ Gabbe S (2012). Obstetrics: Normal and Problem Pregnancies. Elsevier Health Sciences. p. 527. ISBN 978-1-4557-3395-8. Archived from the original on May 15, 2016.
69. Steenland MW, Tepper NK, Curtis KM, Kapp N (November 2011). "Intrauterine contraceptive insertion postabortion: a systematic review". Contraception. 84 (5): 447–64. doi:10.1016/j.contraception.2011.03.007. PMID 22018119.
70. Roe AH, Bartz D (January 2019). "Society of Family Planning clinical recommendations: contraception after surgical abortion". Contraception. 99 (1): 2–9. doi:10.1016/j.contraception.2018.08.016. PMID 30195718.
71. Falcone T, Hurd WW, eds. (2007). Clinical reproductive medicine and surgery. Philadelphia: Mosby. p. 409. ISBN 978-0-323-03309-1. Archived from the original on June 17, 2016.
72. Grimes DA (2007). "Intrauterine Devices (IUDs)". In Hatcher RA, Nelson TJ, Guest F, Kowal D (eds.). Contraceptive Technology (19th ed.).
73. ^ Marnach ML, Long ME, Casey PM (March 2013). "Current issues in contraception". Mayo Clinic Proceedings. 88 (3): 295–9. doi:10.1016/j.mayocp.2013.01.007. PMID 23489454.
74. "Popularity Disparity: Attitudes About the IUD in Europe and the United States". Guttmacher Policy Review. 2007. Archived from the original on March 7, 2010. Retrieved April 27, 2010.
75. Cramer DW (February 2012). "The epidemiology of endometrial and ovarian cancer". Hematology/Oncology Clinics of North America. 26 (1): 1–12. doi:10.1016/j.hoc.2011.10.009. PMC 3259524. PMID 22244658.
76. Adams CE, Wald M (August 2009). "Risks and complications of vasectomy". The Urologic Clinics of North America. 36 (3): 331–6. doi:10.1016/j.ucl.2009.05.009. PMID 19643235.
77. Hillard PA (2008). The 5-minute obstetrics and gynecology consult. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 265. ISBN 978-0-7817-6942-6. Archived from the original on June 11, 2016.
78. "Vasectomy Guideline – American Urological Association". www.auanet.org. Retrieved October 26, 2021.
79. Hillard PA (2008). The 5-minute obstetrics and gynecology consult. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 549. ISBN 978-0-7817-6942-6. Archived from the original on May 5, 2016.
80. Lee Goldman, Andrew I. Schafer, eds. (2020). "Contraception". Goldman-Cecil medicine (26th ed.). Philadelphia, PA: Elsevier. pp. 1568–1575. ISBN 978-0-323-53266-2. OCLC 1118693594.
81. Fahim, M. S., et al. "Heat in male contraception (hot water 60°C, infrared, microwave, and ultrasound)." Contraception 11.5 (1975): 549–562.
82. Fahim, M. S., et al. "Ultrasound as a new method of male contraception." Fertility and sterility 28.8 (1977): 823–831.
83. Fahim, M. S., Z. Fahim, and F. Azzazi. "Effect of ultrasound on testicular electrolytes (sodium and potassium)." Archives of andrology 1.2 (1978): 179–184.
84. Lonidamine analogues for fertility management, WO2011005759A3 WIPO (PCT), Ingrid Gunda GeorgeJoseph S. TashRamappa ChakrsaliSudhakar R. JakkarajJames P. Calvet
85. United States Patent US3934015A, Oral male antifertility method and compositions
86. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB (June 1999). "Poststerilization regret: findings from the United States Collaborative Review of Sterilization". Obstetrics and Gynecology. 93 (6): 889–895. doi:10.1016/s0029-7844(98)00539-0. PMID 10362150. S2CID 38389864.
87. Hatcher R (2008). Contraceptive technology (19th ed.). New York: Ardent Media. p. 390. ISBN 978-1-59708-001-9. Archived from the original on May 6, 2016.
88. Moore DS (2010). The basic practice of statistics (5th ed.). New York: Freeman. p. 25. ISBN 978-1-4292-2426-0. Archived from the original on April 27, 2016.
89. ^ Deffieux X, Morin Surroca M, Faivre E, Pages F, Fernandez H, Gervaise A (May 2011). "Tubal anastomosis after tubal sterilization: a review". Archives of Gynecology and Obstetrics. 283 (5): 1149–58. doi:10.1007/s00404-011-1858-1. PMID 21331539. S2CID 28359350.
90. ^ Shridharani A, Sandlow JI (November 2010). "Vasectomy reversal versus IVF with sperm retrieval: which is better?". Current Opinion in Urology. 20 (6): 503–9. doi:10.1097/MOU.0b013e32833f1b35. PMID 20852426. S2CID 42105503.
91. Nagler HM, Jung H (August 2009). "Factors predicting successful microsurgical vasectomy reversal". The Urologic Clinics of North America. 36 (3): 383–90. doi:10.1016/j.ucl.2009.05.010. PMID 19643240.
92. ^ Grimes DA, Gallo MF, Grigorieva V, Nanda K, Schulz KF (October 2004). "Fertility awareness-based methods for contraception". The Cochrane Database of Systematic Reviews. 2012 (4): CD004860. doi:10.1002/14651858.CD004860.pub2. PMC 8855505. PMID 15495128.
93. Lawrence R (2010). Breastfeeding : a guide for the medical professional (7th ed.). Philadelphia: Saunders. p. 673. ISBN 978-1-4377-0788-5.
94. ^ Freundl G, Sivin I, Batár I (April 2010). "State-of-the-art of non-hormonal methods of contraception: IV. Natural family planning". The European Journal of Contraception & Reproductive Health Care. 15 (2): 113–23. doi:10.3109/13625180903545302. PMID 20141492. S2CID 207523506.
95. Jennings VH, Burke AE (November 1, 2011). "Fertility awareness-based methods". In Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 417–34. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734.
96. Mangone ER, Lebrun V, Muessig KE (January 2016). "Mobile Phone Apps for the Prevention of Unintended Pregnancy: A Systematic Review and Content Analysis". JMIR mHealth and uHealth. 4 (1): e6. doi:10.2196/mhealth.4846. PMC 4738182. PMID 26787311.
97. ^ Medical eligibility criteria for contraceptive use (PDF) (4th ed.). Geneva: Reproductive Health and Research, World Health Organization. 2009. pp. 91–100. ISBN 978-92-4-156388-8. Archived from the original (PDF) on July 9, 2012.
98. ^ Jones RK, Fennell J, Higgins JA, Blanchard K (June 2009). "Better than nothing or savvy risk-reduction practice? The importance of withdrawal". Contraception. 79 (6): 407–10. doi:10.1016/j.contraception.2008.12.008. PMID 19442773.
99. Killick SR, Leary C, Trussell J, Guthrie KA (March 2011). "Sperm content of pre-ejaculatory fluid". Human Fertility. 14 (1): 48–52. doi:10.3109/14647273.2010.520798. PMC 3564677. PMID 21155689.
100. ^ "Abstinence". Planned Parenthood. 2009. Archived from the original on September 10, 2009. Retrieved September 9, 2009.
101. Murthy AS, Harwood B (2007). "Contraception Update". Primary Care in Obstetrics and Gynecology (2nd ed.). New York: Springer. pp. 241–264. doi:10.1007/978-0-387-32328-2_12. ISBN 978-0-387-32327-5.
102. Alters S, Schiff W (October 5, 2009). Essential Concepts for Healthy Living. Jones & Bartlett Publishers. p. 116. ISBN 978-0-7637-5641-3. Retrieved December 30, 2017.
103. Greenberg JS, Bruess CE, Oswalt SB (2016). Exploring the Dimensions of Human Sexuality. Jones & Bartlett Publishers. p. 191. ISBN 978-1-4496-9801-0. Retrieved December 30, 2017.
104. Fortenberry JD (April 2005). "The limits of abstinence-only in preventing sexually transmitted infections". The Journal of Adolescent Health. 36 (4): 269–70. doi:10.1016/j.jadohealth.2005.02.001. PMID 15780781.
105. Best K (2005). "Nonconsensual Sex Undermines Sexual Health". Network. 23 (4). Archived from the original on February 18, 2009.
106. Francis L (2017). The Oxford Handbook of Reproductive Ethics. Oxford University Press. p. 329. ISBN 978-0-19-998187-8. Retrieved December 30, 2017.
107. Thomas RM (2009). Sex and the American teenager seeing through the myths and confronting the issues. Lanham, MD: Rowman & Littlefield Education. p. 81. ISBN 978-1-60709-018-2.
108. Edlin G (2012). Health & Wellness. Jones & Bartlett Learning. p. 213. ISBN 978-1-4496-3647-0.
109. ^ Santelli JS, Kantor LM, Grilo SA, Speizer IS, Lindberg LD, Heitel J, et al. (September 2017). "Abstinence-Only-Until-Marriage: An Updated Review of U.S. Policies and Programs and Their Impact". The Journal of Adolescent Health. 61 (3): 273–280. doi:10.1016/j.jadohealth.2017.05.031. hdl:1805/15683. PMID 28842065.
110. Kowal D (2007). "Abstinence and the Range of Sexual Expression". In Hatcher RA, et al. (eds.). Contraceptive Technology (19th rev. ed.). New York: Ardent Media. pp. 81–86. ISBN 978-0-9664902-0-6.
111. Blackburn ST (2007). Maternal, fetal, & neonatal physiology : a clinical perspective (3rd ed.). St. Louis, MO: Saunders Elsevier. p. 157. ISBN 978-1-4160-2944-1. Archived from the original on May 12, 2016.
112. "WHO 10 facts on breastfeeding". World Health Organization. April 2005. Archived from the original on June 23, 2013.
113. Van der Wijden C, Manion C (October 2015). "Lactational amenorrhoea method for family planning". The Cochrane Database of Systematic Reviews. 2015 (10): CD001329. doi:10.1002/14651858.CD001329.pub2. PMC 6823189. PMID 26457821.
114. ^ Fritz M (2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 1007–08. ISBN 978-1-4511-4847-3. Archived from the original on June 3, 2016.
115. Swisher J, Lauwers A (October 25, 2010). Counseling the nursing mother a lactation consultant's guide (5th ed.). Sudbury, MA: Jones & Bartlett Learning. pp. 465–66. ISBN 978-1-4496-1948-0. Archived from the original on June 16, 2016.
116. Office of Population Research, Association of Reproductive Health Professionals (July 31, 2013). "What is the difference between emergency contraception, the 'morning after pill', and the 'day after pill'?". Princeton: Princeton University. Archived from the original on September 23, 2013. Retrieved September 7, 2013.
117. ^ Leung VW, Levine M, Soon JA (February 2010). "Mechanisms of action of hormonal emergency contraceptives". Pharmacotherapy. 30 (2): 158–68. doi:10.1592/phco.30.2.158. PMID 20099990. S2CID 41337748. The evidence strongly supports disruption of ovulation as a mechanism of action. The data suggest that emergency contraceptives are unlikely to act by interfering with implantation
118. ^ Shen J, Che Y, Showell E, Chen K, Cheng L, et al. (Cochrane Fertility Regulation Group) (January 2019). "Interventions for emergency contraception". The Cochrane Database of Systematic Reviews. 1 (1): CD001324. doi:10.1002/14651858.CD001324.pub6. PMC 7055045. PMID 30661244.
119. Kripke C (September 2007). "Advance provision for emergency oral contraception". American Family Physician. 76 (5): 654. PMID 17894132.
120. Shrader SP, Hall LN, Ragucci KR, Rafie S (September 2011). "Updates in hormonal emergency contraception". Pharmacotherapy. 31 (9): 887–95. doi:10.1592/phco.31.9.887. PMID 21923590. S2CID 33900390.
121. Beeston A (January 27, 2022). "Pharmacists gave the POP with emergency contraception". NIHR Evidence. doi:10.3310/alert_48882. Retrieved May 31, 2024.
122. Cameron ST, Glasier A, McDaid L, Radley A, Patterson S, Baraitser P, Stephenson J, Gilson R, Battison C, Cowle K, Vadiveloo T, Johnstone A, Morelli A, Goulao B, Forrest M (May 5, 2021). "Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT". Health Technology Assessment. 25 (27): 1–92. doi:10.3310/hta25270. hdl:2164/16696. ISSN 2046-4924.
123. Richardson AR, Maltz FN (January 2012). "Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception". Clinical Therapeutics. 34 (1): 24–36. doi:10.1016/j.clinthera.2011.11.012. PMID 22154199.
124. "Update on Emergency Contraception". Association of Reproductive Health Professionals. March 2011. Archived from the original on May 11, 2013. Retrieved May 20, 2013.
125. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J (July 2012). "The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience". Human Reproduction. 27 (7): 1994–2000. doi:10.1093/humrep/des140. PMC 3619968. PMID 22570193.
126. Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, et al. (October 2011). "Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel". Contraception. 84 (4): 363–7. doi:10.1016/j.contraception.2011.02.009. PMID 21920190.
127. "Dual protection against unwanted pregnancy and HIV / STDs". Sexual Health Exchange (3): 8. 1998. PMID 12294688.
128. ^ Cates W, Steiner MJ (March 2002). "Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach?". Sexually Transmitted Diseases. 29 (3): 168–74. doi:10.1097/00007435-200203000-00007. PMID 11875378. S2CID 42792667.
129. Farber NA, Farber NA (May 2000). "Statement on Dual Protection against Unwanted Pregnancy and Sexually Transmitted Infections, including HIV". Terapevticheskii Arkhiv. 53 (10). International Planned Parenthood Federation: 135–140. Archived from the original on April 10, 2016.
130. Gupta RC (2011). Reproductive and Developmental Toxicology. Academic Press. p. 105. ISBN 978-0-12-382032-7. Archived from the original on May 16, 2016.
131. Bhakta J, Bainbridge J, Borgelt L (November 2015). "Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy". Epilepsy & Behavior. 52 (Pt A): 212–7. doi:10.1016/j.yebeh.2015.08.004. PMID 26460786. S2CID 6504198.
132. Country Comparison: Maternal Mortality Rate Archived November 8, 2012, at the Wayback Machine in The CIA World Factbook
133. ^ Sholapurkar SL (February 2010). "Is there an ideal interpregnancy interval after a live birth, miscarriage or other adverse pregnancy outcomes?". Journal of Obstetrics and Gynaecology. 30 (2): 107–10. doi:10.3109/01443610903470288. PMID 20143964. S2CID 6346721.
134. Lavin C, Cox JE (August 2012). "Teen pregnancy prevention: current perspectives". Current Opinion in Pediatrics. 24 (4): 462–9. doi:10.1097/MOP.0b013e3283555bee. PMID 22790099. S2CID 12022584.
135. ^ Robbins CL, Ott MA (October 2017). "Contraception options and provision to adolescents". Minerva Pediatrica. 69 (5): 403–414. doi:10.23736/s0026-4946.17.05026-5. hdl:1805/14082. PMID 28643995.
136. ^ Britton LE, Alspaugh A, Greene MZ, McLemore MR (February 2020). "CE: An Evidence-Based Update on Contraception". The American Journal of Nursing. 120 (2): 22–33. doi:10.1097/01.NAJ.0000654304.29632.a7. PMC 7533104. PMID 31977414.
137. ^ Tsui AO, McDonald-Mosley R, Burke AE (April 2010). "Family planning and the burden of unintended pregnancies". Epidemiologic Reviews. 32 (1): 152–74. doi:10.1093/epirev/mxq012. PMC 3115338. PMID 20570955.
138. ^ Rosenthal E (June 30, 2013). "American Way of Birth, Costliest in the World". New York Times. Archived from the original on March 14, 2017.
139. "Expenditures on Children by Families, 2011". United States Department of Agriculture, Center for Nutrition Policy and Promotion. Archived from the original on March 8, 2008. Retrieved August 29, 2012.
140. "Demand for family planning satisfied by modern methods". Our World in Data. Retrieved March 5, 2020.
141. ^ Darroch JE (March 2013). "Trends in contraceptive use". Contraception. 87 (3): 259–63. doi:10.1016/j.contraception.2012.08.029. PMID 23040137.
142. Darney L, Speroff PD (2010). A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. p. 315. ISBN 978-1-60831-610-6.
143. Naz RK, Rowan S (June 2009). "Update on male contraception". Current Opinion in Obstetrics & Gynecology. 21 (3): 265–9. doi:10.1097/gco.0b013e328329247d. PMID 19469045. S2CID 40507937.
144. Cleland JG, Ndugwa RP, Zulu EM (February 2011). "Family planning in sub-Saharan Africa: progress or stagnation?". Bulletin of the World Health Organization. 89 (2): 137–43. doi:10.2471/BLT.10.077925 (inactive December 5, 2024). PMC 3040375. PMID 21346925.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
145. ^ Darroch JE, Singh S (May 2013). "Trends in contraceptive need and use in developing countries in 2003, 2008, and 2012: an analysis of national surveys". Lancet. 381 (9879): 1756–62. doi:10.1016/S0140-6736(13)60597-8. PMID 23683642. S2CID 8257042.
146. ^ Rasch V (July 2011). "Unsafe abortion and postabortion care – an overview". Acta Obstetricia et Gynecologica Scandinavica. 90 (7): 692–700. doi:10.1111/j.1600-0412.2011.01165.x. PMID 21542813. S2CID 27737728.
147. ^ Cuomo A (2010). "Birth control". In O'Reilly A (ed.). Encyclopedia of motherhood. Thousand Oaks, CA: Sage Publications. pp. 121–26. ISBN 978-1-4129-6846-1.
148. Lipsey RG, Carlaw K, Bekar C (2005). "Historical Record on the Control of Family Size". Economic Transformations: General Purpose Technologies and Long-Term Economic Growth. Oxford University Press. pp. 335–40. ISBN 978-0-19-928564-8.
149. ^ unspecified (2001). "Herbal contraceptives and abortifacients". In Bullough VL (ed.). Encyclopedia of birth control. Santa Barbara, CA: ABC-CLIO. pp. 125–28. ISBN 978-1-57607-181-6.
150. Totelin LM (2009). Hippocratic Recipes: Oral and Written Transmission of Pharmacological Knowledge in Fifth- and Fourth-Century Greece. Leiden, Netherlands; Boston: Brill. pp. 158–61. ISBN 978-90-04-17154-1.
151. ^ Carrick PJ (2001). Medical Ethics in Ancient World. Washington, DC: Georgetown University Press. pp. 119–22. ISBN 978-1-58901-861-7.
152. McTavish L (2007). "Contraception and birth control". In Robin D (ed.). Encyclopedia of women in the Renaissance : Italy, France, and England. Santa Barbara, CA: ABC-CLIO. pp. 91–92. ISBN 978-1-85109-772-2.
153. ^ "A History of Birth Control Methods" (PDF). Planned Parenthood Report. January 2012. Archived (PDF) from the original on November 6, 2015.
154. Hartmann B (1997). "Population control I: Birth of an ideology". International Journal of Health Services. 27 (3): 523–40. doi:10.2190/bl3n-xajx-0yqb-vqbx. PMID 9285280. S2CID 39035850.
155. Simms M (January 27, 1977). "Review: A History of the Malthusian League 1877–1927". New Scientist. Archived from the original on May 5, 2016.
156. d'Arcy F (November 1977). "The Malthusian League and the resistance to birth control propaganda in late Victorian Britain". Population Studies. 31 (3): 429–48. doi:10.2307/2173367. JSTOR 2173367. PMID 11630505.
157. Meyer JE (2004). Any friend of the movement: networking for birth control, 1920–1940. Ohio State University Press. p. 184. ISBN 978-0-8142-0954-7. Archived from the original on January 3, 2014.
158. Galvin R (1998). "Margaret Sanger's "Deeds of Terrible Virtue"". National Endowment for the Humanities. Archived from the original on October 1, 2013. Retrieved January 27, 2014.
159. Rossi A (1988). The Feminist Papers. Boston: Northeastern University Press. p. 523. ISBN 978-1-55553-028-0.
160. ^ "Biographical Sketch". About Sanger. New York University. Archived from the original on June 28, 2017. Retrieved February 24, 2017.
161. Pastorello K (2013). The Progressives: Activism and Reform in American Society, 1893–1917. John Wiley & Sons. p. 65. ISBN 978-1-118-65112-4. Archived from the original on June 4, 2016.
162. Zorea A (2012). Birth Control. Santa Barbara, CA: Greenwood. p. 43. ISBN 978-0-313-36254-5.
163. Baker JH (2012). Margaret Sanger : a life of passion (First pbk. ed.). Farrar, Straus and Giroux. pp. 115–17. ISBN 978-1-4299-6897-3. Archived from the original on May 4, 2016.
164. McCann CR (2010). "Women as Leaders in the Contraceptive Movement". In O'Connor K (ed.). Gender and Women's Leadership: A Reference Handbook. Sage. p. 751. ISBN 978-1-84885-583-0. OCLC 568741234. Archived from the original on June 10, 2016.
165. Küenzl J, Schwabenland C, Elmaco J, Hale S, Levi E, Chen M, et al. (2010), "International Planned Parenthood Federation", International Encyclopedia of Civil Society, pp. 891–892, doi:10.1007/978-0-387-93996-4_403, ISBN 978-0-387-93994-0
166. ^ "The Bitter Pill: Harvard and the Dark History of Birth Control | Magazine | The Harvard Crimson". www.thecrimson.com. Retrieved December 14, 2021.
167. Seaman B (2003). The greatest experiment ever performed on women : exploding the estrogen myth. New York: Hyperion. ISBN 978-0-7868-6853-7. OCLC 52515011.
168. "Puerto Ricans recall being guinea pigs for 'magic pill'". Chicago Tribune. April 11, 2004. Retrieved December 14, 2021.
169. ^ Buenker JD, Kantowicz ER, eds. (1988). Historical dictionary of the Progressive Era, 1890–1920. New York: Greenwood Press. ISBN 978-0313243097. OCLC 17807492.
170. McGerr M (2014). A fierce discontent : the rise and fall of the progressive movement in a. Free Press. ISBN 9781439136034. OCLC 893124592.
171. Hall R (1977). Passionate Crusader. Harcourt, Brace, Jovanovich. p. 186. ISBN 9780151712885.
172. Stopes MC (1925). The First Five Thousand. London: John Bale, Sons & Danielsson. p. 9. OCLC 12690936.
173. ^ "Family Planning Timeline". Congressional Digest. 2015.
174. Herbert M (September 5, 2012). "Salford's birth control pioneers". The Guardian. Archived from the original on May 28, 2015. Retrieved May 28, 2015.
175. Hall L (2011). The life and times of Stella Browne : feminist and free spirit. London: I.B. Tauris. p. 173. ISBN 978-1-84885-583-0.
176. BCIC Memorandum on Proposed Re-organisation . Wellcome Library, Archives of the Eugenics Society (WL/SA/EUG/D/12/12.)
177. Wright H (1935). Birth Control: Advice on Family Spacing and Healthy Sex Life. London: Cassell's Health Handbooks.
178. Szuhan N (September 2018). "Sex in the laboratory: the Family Planning Association and contraceptive science in Britain, 1929–1959". British Journal for the History of Science. 51 (3): 487–510. doi:10.1017/S0007087418000481. PMID 29952279. S2CID 49474491.
179. Birth Control Investigation Committee Statement of Intent , Wellcome Library, Archives of the Family Planning Association (WL/SA/FPA), WL/SA/FPA/A13/5.
180. Bailey MJ (2013). "Fifty Years of Family Planning: New Evidence on the Long-Run Effects of Increasing Access to Contraception". Brookings Papers on Economic Activity. 2013: 341–409. doi:10.1353/eca.2013.0001. ISSN 0007-2303. PMC 4203450. PMID 25339778.
181. "Public Attitudes about Birth Control | Roper Center for Public Opinion Research". ropercenter.cornell.edu. Retrieved December 19, 2023.
182. "BIRTH CONTROL AID AT PEAK IN NATION; 374 Clinics Now Operating, an Increase of 87 in a Year, League Reports". The New York Times. January 27, 1938. ISSN 0362-4331. Retrieved June 21, 2022.
183. Doan A (2007). Opposition and Intimidation: The Abortion Wars and Strategies of Political Harassment. University of Michigan Press. pp. 53–54. ISBN 978-0-472-06975-0.
184. "Griswold v. Connecticut: Landmark Case Remembered", by Andi Reardon. NY Times, May 28, 1989
185. "Catherine Roraback, 87, Influential Lawyer, Dies" by Dennis Hevesi Oct. 20, 2007.
186. "History of Birth Control in the United States". Congressional Digest. 2012.
187. "Birth control benefits and reproductive health care options in the Health Insurance Marketplace". HealthCare.gov. Archived from the original on February 12, 2016. Retrieved February 17, 2016.
188. Fritz MA, Speroff L (2011). "Intrauterine contraception". Clinical gynecologic endocrinology and infertility (8th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. pp. 1095–98. ISBN 978-0-7817-7968-5. Archived from the original on November 16, 2016.
189. "American Experience | The Pill | Timeline". www.pbs.org. Archived from the original on October 1, 2016. Retrieved October 20, 2016.
190. Poston D (2010). Population and Society: An Introduction to Demography. Cambridge University Press. p. 98. ISBN 978-1-139-48938-6. Archived from the original on November 16, 2016.
191. Zhang J, Zhou K, Shan D, Luo X (May 2022). "Medical methods for first trimester abortion". The Cochrane Database of Systematic Reviews. 2022 (5): CD002855. doi:10.1002/14651858.CD002855.pub5. PMC 9128719. PMID 35608608.
192. Cottingham J, Germain A, Hunt P (July 2012). "Use of human rights to meet the unmet need for family planning". Lancet. 380 (9837): 172–80. doi:10.1016/S0140-6736(12)60732-6. PMID 22784536. S2CID 41854959.
193. Doan A (2007). Opposition and Intimidation: The Abortion Wars and Strategies of Political Harassment. University of Michigan Press. pp. 62–63. ISBN 978-0-472-06975-0.
194. Singh S, Darroch JE (June 2012). "Adding It Up: Costs and Benefits of Contraceptive Services Estimates for 2012" (PDF). Guttmacher Institute and United Nations Population Fund (UNFPA), 201. Archived (PDF) from the original on August 5, 2012.
195. ACOG (September 9, 2014). "ACOG Statement on OTC Access to Contraception". Archived from the original on September 10, 2014. Retrieved September 11, 2014.
196. Garner AC, Michel AR (November 4, 2016). ""The Birth Control Divide": U.S. Press Coverage of Contraception, 1873–2013". Journalism & Communication Monographs. 18 (4): 180–234. doi:10.1177/1522637916672457. S2CID 151781215.
197. Srikanthan A, Reid RL (February 2008). "Religious and cultural influences on contraception". Journal of Obstetrics and Gynaecology Canada. 30 (2): 129–137. doi:10.1016/s1701-2163(16)32736-0. PMID 18254994.
198. Pope Paul VI (July 25, 1968). "Humanae Vitae: Encyclical of Pope Paul VI on the Regulation of Birth". Vatican. Archived from the original on August 24, 2000. Retrieved October 1, 2006.
199. Ruether RR (2006). "Women in North American Catholicism". In Keller RS (ed.). Encyclopedia of women and religion in North America. Bloomington, IN : Indiana Univ. Press. p. 132. ISBN 978-0-253-34686-5. Archived from the original on May 29, 2016.
200. Digby B, Ferretti J, Flintoff I, Owen A, Ryan C (2001). Digby B (ed.). Heinemann 16–19 Geography: Global Challenges Student Book (2nd ed.). Heinemann. p. 158. ISBN 978-0-435-35249-3. Archived from the original on May 12, 2016.
201. Rengel M (2000). Encyclopedia of birth control. Phoenix, AZ: Oryx Press. p. 202. ISBN 978-1-57356-255-3. Archived from the original on June 3, 2016.
202. Harakas SS (August 12, 1985). "The Stand of the Orthodox Church on Controversial Issues – Society Articles – Greek Orthodox Archdiocese of America". Greek Orthodox Archdiocese of America. Retrieved September 5, 2019.
203. Bennett JA (2008). Water is thicker than blood : an Augustinian theology of marriage and singleness. Oxford: Oxford University Press. p. 178. ISBN 978-0-19-531543-1. Archived from the original on May 28, 2016.
204. Feldman DM (1998). Birth Control in Jewish Law. Lanham, MD: Jason Aronson. ISBN 978-0-7657-6058-6.
205. "Hindu Beliefs and Practices Affecting Health Care". University of Virginia Health System. Archived from the original on March 23, 2004. Retrieved October 6, 2006.
206. "More Questions & Answers on Buddhism: Birth Control and Abortion". Alan Khoo. Archived from the original on June 29, 2008. Retrieved June 14, 2008.
207. Akbar KF. "Family Planning and Islam: A Review". Hamdard Islamicus. XVII (3). Archived from the original on September 26, 2006.
208. ^ "World Contraception Day". Archived from the original on August 18, 2014.
209. Hutcherson H (2002). What your mother never told you about s.e.x (1st Perigee ed.). New York: Perigee Book. p. 201. ISBN 978-0-399-52853-8. Archived from the original on June 29, 2016.
210. Rengel M (2000). Encyclopedia of birth control. Phoenix, AZ: Oryx Press. p. 65. ISBN 978-1-57356-255-3. Archived from the original on May 6, 2016.
211. Cottrell BH (March–April 2010). "An updated review of evidence to discourage douching". MCN: The American Journal of Maternal/Child Nursing. 35 (2): 102–7, quiz 108–9. doi:10.1097/NMC.0b013e3181cae9da. PMID 20215951. S2CID 46715131.
212. Alexander W (2013). New Dimensions In Women's Health – Book Alone (6th ed.). Jones & Bartlett Publishers. p. 105. ISBN 978-1-4496-8375-7. Archived from the original on May 6, 2016.
213. Sharkey H (2013). Need to Know Fertility and Conception and Pregnancy. HarperCollins. p. 17. ISBN 978-0-00-751686-5. Archived from the original on June 3, 2016.
214. Strange M (2011). Encyclopedia of women in today's world. Thousand Oaks, CA: Sage Reference. p. 928. ISBN 978-1-4129-7685-5. Archived from the original on May 15, 2016.
215. Girum T, Wasie A (December 2018). "Return of fertility after discontinuation of contraception: a systematic review and meta-analysis". Contraception and Reproductive Medicine. 3 (1): 9. doi:10.1186/s40834-018-0064-y. PMC 6055351. PMID 30062044.
216. "Access to Contraception - ACOG". www.acog.org.
217. "Who's Impacted by Attacks on Birth Control". www.plannedparenthoodaction.org. Retrieved October 15, 2019.
218. Brown SS, Eisenberg L, et al. (Institute of Medicine (US) Committee on Unintended Pregnancy) (1995). Socioeconomic and Cultural Influences on Contraceptive Use. National Academies Press (US).
219. "Just the Facts: Latinas & Contraception" (PDF). Archived from the original (PDF) on September 26, 2020. Retrieved March 25, 2020.
220. Dehlendorf C, Rodriguez MI, Levy K, Borrero S, Steinauer J (March 2010). "Disparities in family planning". American Journal of Obstetrics and Gynecology. 202 (3): 214–20. doi:10.1016/j.ajog.2009.08.022. PMC 2835625. PMID 20207237.
221. "Where can I get contraception?". NHS. December 21, 2017. Retrieved June 7, 2022.
222. "Your contraception guide". NHS. December 21, 2017. Retrieved June 7, 2022.
223. Willsher K (September 9, 2021). "France to offer free contraception to women under 25". The Guardian. Paris. Retrieved June 7, 2022.
224. Conneely A (October 12, 2021). "Free contraception for women aged 17–25 from August". RTÉ. Retrieved June 7, 2022.
225. "Minister Donnelly secures free contraception for women aged between 17–25 years in Budget 2022". Gov.ie. Department of Health. October 22, 2021. Retrieved June 7, 2022.
226. ^ Swan LE (December 2021). "The impact of US policy on contraceptive access: a policy analysis". Reproductive Health. 18 (1): 235. doi:10.1186/s12978-021-01289-3. ISSN 1742-4755. PMC 8607408. PMID 34809673.
227. Sonfield A, Gold RB, Frost JJ, Darroch JE (March 2004). "U.S. Insurance Coverage of Contraceptives and the Impact Of Contraceptive Coverage Mandates". Perspectives on Sexual and Reproductive Health. 36 (2): 72–79. doi:10.1363/3607204. ISSN 1538-6341.
228. "#FreeThePill Youth Council". Advocates for Youth. Retrieved June 7, 2022.
229. Over-the-counter birth control? Drugmaker seeks FDA approval, AP News July 11, 2022
230. Ibis celebrates the first-ever application for an OTC birth control pill in the United States, Ibis Reproductive Health July 2022
231. Belluck P (July 13, 2023). "F.D.A. Approves First U.S. Over-the-Counter Birth Control Pill". The New York Times. ISSN 0362-4331. Retrieved July 13, 2023.
232. ^ Jensen JT (October 2011). "The future of contraception: innovations in contraceptive agents: tomorrow's hormonal contraceptive agents and their clinical implications". American Journal of Obstetrics and Gynecology. 205 (4 Suppl): S21-5. doi:10.1016/j.ajog.2011.06.055. PMID 21961821.
233. Halpern V, Raymond EG, Lopez LM (September 2014). "Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy". The Cochrane Database of Systematic Reviews. 2014 (9): CD007595. doi:10.1002/14651858.CD007595.pub3. PMC 7196890. PMID 25259677.
234. ^ Castaño PM, Adekunle L (March 2010). "Transcervical sterilization". Seminars in Reproductive Medicine. 28 (2): 103–9. doi:10.1055/s-0030-1248134. PMID 20352559. S2CID 260317985.
235. Rabin RC (November 21, 2016). "Bayer's Essure Contraceptive Implant, Now With a Warning". The New York Times. ISSN 0362-4331. Retrieved May 1, 2020.
236. Office of the Commissioner (March 24, 2020). "FDA takes additional action to better understand safety of Essure, inform patients of potential risks". FDA. Retrieved May 1, 2020.
237. Kaplan S (July 20, 2018). "Bayer Will Stop Selling the Troubled Essure Birth Control Implants". The New York Times. ISSN 0362-4331. Retrieved May 1, 2020.
238. Friedman M (2019). "Interest Among U.S. Men for New Male Contraceptive Options" (PDF). Male Contraceptive Initiative. Retrieved October 12, 2023.
239. Glasier A (November 2010). "Acceptability of contraception for men: a review". Contraception. 82 (5): 453–456. doi:10.1016/j.contraception.2010.03.016. PMID 20933119.
240. Roth MY, Shih G, Ilani N, Wang C, Page ST, Bremner WJ, et al. (October 2014). "Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial". Contraception. 90 (4): 407–412. doi:10.1016/j.contraception.2014.05.013. PMC 4269220. PMID 24981149.
241. Wang CC. "Male Birth Control Is in Development, but Barriers Still Stand in the Way". Scientific American. Retrieved October 12, 2023.
242. "Birth control for men". Chemical & Engineering News. Retrieved October 12, 2023.
243. Sitruk-Ware R (May 11, 2018). "Getting contraceptives for men to the market will take pharma's help". STAT. Retrieved October 12, 2023.
244. "G-FINDER data portal". Policy Cures Research. Retrieved October 12, 2023.
245. "CDP Research: Developing Hormonal Contraception Methods for Men | NICHD – Eunice Kennedy Shriver National Institute of Child Health and Human Development". www.nichd.nih.gov. February 16, 2022. Retrieved October 12, 2023.
246. Gorvett Z. "The weird reasons there still isn't a male contraceptive pill". BBC Future.
247. Gibbens S (March 3, 2023). "Birth control options for men are advancing. Here's how they work". National Geographic Magazine. Archived from the original on March 3, 2023. Retrieved October 12, 2023.
248. Barber R (December 4, 2022). "In the hunt for a male contraceptive, scientists look to stop sperm in their tracks". National Public Radio. Retrieved October 12, 2023.
249. Chiu A (April 14, 2022). "Why there's still no new birth control for men". Washington Post. Retrieved October 12, 2023.
250. Blum D (March 25, 2022). "Despite Encouraging Research, a Male Birth Control Pill Remains Elusive". The New York Times. ISSN 0362-4331. Retrieved October 12, 2023.
251. "What Is In Development". Male Contraceptive Initiative. Retrieved October 12, 2023.
252. Anderson DJ, Johnston DS (April 2023). "A brief history and future prospects of contraception". Science. 380 (6641): 154–158. Bibcode:2023Sci...380..154A. doi:10.1126/science.adf9341. PMC 10615352. PMID 37053322. S2CID 258112296.
253. Abbe CR, Page ST, Thirumalai A (September 2020). "Male Contraception". The Yale Journal of Biology and Medicine. 93 (4): 603–613. PMC 7513428. PMID 33005125.
254. Holdaway J, Georg GI (May 24, 2024). "An emerging target for male contraception". Science. 384 (6698): 849–850. Bibcode:2024Sci...384..849H. doi:10.1126/science.adp6432. ISSN 0036-8075. PMID 38781397.
255. Millar L (2011). Infectious Disease Management in Animal Shelters. John Wiley & Sons. ISBN 978-1-119-94945-9. Archived from the original on May 3, 2016.
256. Ackerman L, ed. (2007). Blackwell's five-minute veterinary practice management consult (1st ed.). Ames, IO: Blackwell Pub. p. 80. ISBN 978-0-7817-5984-7. Archived from the original on June 10, 2016.
257. Boyle R (March 3, 2009). "Birth control for animals: a scientific approach to limiting the wildlife population explosion". Popular Science. New York: PopSci.com. Archived from the original on May 25, 2012.
258. Kirkpatrick JF, Lyda RO, Frank KM (July 2011). "Contraceptive vaccines for wildlife: a review". American Journal of Reproductive Immunology. 66 (1): 40–50. doi:10.1111/j.1600-0897.2011.01003.x. PMID 21501279. S2CID 3890080.
259. Levy JK (July 2011). "Contraceptive vaccines for the humane control of community cat populations". American Journal of Reproductive Immunology. 66 (1): 63–70. doi:10.1111/j.1600-0897.2011.01005.x. PMC 5567843. PMID 21501281.
260. "Goat 'condoms' save Kenyan herds". BBC News. October 6, 2008. Archived from the original on October 6, 2008. Retrieved October 6, 2008.

Further reading

• Speroff L, Darney PD (2010). A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 242–43. ISBN 978-1-60831-610-6. Archived from the original on May 6, 2016.
• Stubblefield PG, Roncari DM (2011). "Family Planning". In Berek JS (ed.). Berek & Novak's Gynecology (15th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 211–69. ISBN 978-1-4511-1433-1.
• Jensen JT, Mishell Jr DR (March 2012). "Family Planning: Contraception, Sterilization, and Pregnancy Termination". In Lentz GM, Lobo RA, Gershenson DM, Katz VL (eds.). Comprehensive Gynecology (6th ed.). Philadelphia: Mosby Elsevier. pp. 215–72. ISBN 978-0-323-06986-1.
• Gavin L, Moskosky S, Carter M, Curtis K, Glass E, Godfrey E, et al. (Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC) (April 2014). "Providing quality family planning services: Recommendations of CDC and the U.S. Office of Population Affairs". MMWR. Recommendations and Reports. 63 (RR-04): 1–54. PMID 24759690.
• World Health Organization Department of Reproductive Health and Research and Johns Hopkins Bloomberg School of Public Health (2011). Family planning: A global handbook for providers: Evidence-based guidance developed through worldwide collaboration (PDF) (Rev. and Updated ed.). Geneva: WHO and Center for Communication Programs. ISBN 978-0-9788563-7-3.
• Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, Whiteman MK (July 2016). "U.S. Selected Practice Recommendations for Contraceptive Use, 2016". MMWR. Recommendations and Reports. 65 (4): 1–66. doi:10.15585/mmwr.rr6504a1. PMID 27467319.
• Shoupe D (2020). The Handbook of Contraception: Evidence Based Practice Recommendations and Rationales. Cham: Humana Press. doi:10.1007/978-3-030-46391-5. ISBN 978-3-030-46390-8.

External links

• Resources in your library
• Resources in other libraries

• "WHO Fact Sheet". July 2017. Retrieved July 23, 2017.
• "Birth Control Comparison Chart". Cedar River Clinics.
• Bulk procurement of birth control by the World Health Organization

v t e Women's health
Reproductive health	Reproductive tract External female genitalia (vulva) Clitoris Clitoral hood Labia minora Labia majora Vagina Cervix Uterus Fallopian tube Ovary Reproductive system disease Maternal health Pregnancy Unintended pregnancy Gravidity and parity Obstetrics Antenatal care Adolescent pregnancy Complications of pregnancy Hyperemesis gravidarum Ectopic pregnancy Miscarriage Obstetrical bleeding Gestational diabetes Hypertension Preeclampsia Eclampsia Childbirth Midwifery Preterm birth Multiple births Oxytocin Obstructed labor Cesarian section Retained placenta Obstetrical fistulae Vesicovaginal fistula Rectovaginal fistula Episiotomy Husband stitch Postpartum care Postpartum confinement Maternal deaths Perinatal mortality Stillbirths Abortion Mother-to-child transmission Sterilization Compulsory sterilization Breastfeeding and mental health Reproductive life plan Infertility Childlessness Assisted reproductive technology In vitro fertilization Parenting Adoption Fostering Contraception and family planning Intrauterine devices Oral contraceptives Condoms Male contraceptive Contraceptive prevalence Contraceptive security Planned parenthood Fertility awareness Menstruation Culture and menstruation Feminine hygiene Menarche Menstrual cycle Menstrual aids Cloth menstrual pad Menstrual cup Tampon Sanitary pad Dysmenorrhea Menorrhagia Amenorrhoea Menopause Hormone replacement therapy
Sexual health	Sexually transmitted infections Safe sex HIV Human papilloma virus HPV vaccine Pelvic inflammatory disease Female genital mutilation Clitoridectomy Infibulation Breast binding Breast health Breast ironing Child marriage Dyspareunia Forced marriage Gynaecological disorders Vaginitis Leblouh Polygamy Sexual intercourse Orgasm Puberty Sex differences Sex education
Non-reproductive health	Violence against women Abuse during childbirth Domestic violence Pregnancy Intimate partner violence Misogyny Sexual harassment Sexual assault Rape Femicide Gender discrimination Non-communicable diseases Cancer Lung cancer Breast cancer Uterine cancer Endometrial cancer Cervical cancer Papanicolaou test Ovarian cancer Cardiovascular disease Dementia Alzheimer's disease Bone health Osteoporosis Hip fracture Anaemia Mental health Anxiety Depression Major depressive disorder Urinary tract Urethra Urinary tract infection Urinary incontinence
Sociocultural factors	Poverty Disadvantaged Gender equality Healthcare inequality Gender disparities in health Social determinants of health Reproductive justice Women's empowerment
Politics, research and advocacy	United Nations The Convention on the Elimination of All Forms of Discrimination against Women Declaration on the elimination of violence against women International Day of the Girl Child Commission on the Status of Women UN Women United States Office of Research on Women's Health Women's Health Initiative International Center for Research on Women Nurses' Health Study Black Women's Health Study Cartwright Inquiry Society for Women's Health Research
Women's health by country	China Ethiopia India Family planning Russia Birth control in the United States
Category Commons WikiProject

• Feminism
• Medicine
• Science

• Birth control
• Women's health
• Reproductive rights in the United States